Spanish Luxury Stock News

BME:MRL
BME:MRLREITs

MERLIN Properties (BME:MRL) Data Centers Fuel FFO Reset As Risks Persist

MERLIN Properties SOCIMI closed at €14.85 after a soft patch in recent weeks, even though the latest quarter put one figure squarely in the spotlight. Funds From Operations, the core cash earnings metric for a real estate investment trust, reached €180 million in Q2 and marked a clear reset after last year’s swings from one off gains and charges. The market is still treating the stock like an ordinary landlord, while the results lean heavily on the emerging data center engine that management...
BME:LDA
BME:LDAInsurance

Línea Directa (BME:LDA) Stock Trades On Strong Profits And Motor Risk

Línea Directa Aseguradora Compañía de Seguros y Reaseguros went into today trading at €1.26 after a steady few months, with the stock up about 6% over 90 days. The market has been pricing in a mixed story, yet H1 2026 came through with a clear headline. Net profit reached €52.1m with a return on equity of 23.3%, and the Solvency II capital ratio stood at 196.3% even after an interim dividend. In the short term, that combination of profitability and capital strength is what drew attention. The...
BME:HOME
BME:HOMEConsumer Durables

Neinor Homes (BME:HOME) Profit Surge Runs Into Interest Coverage Strain

Neinor Homes closed at €16.27 after a muted few months, with the stock roughly flat over 90 days. Today’s H1 2026 release puts the focus squarely on profit quality rather than price action. The headline is a solid profit print sitting on top of a balance sheet that still carries meaningful interest costs, with trailing net margin at 10.7% and management flagging that interest payments are not comfortably covered by earnings. Short term traders may shrug. Long term holders now have to weigh...
BME:ROVI
BME:ROVIPharmaceuticals

Laboratorios Farmaceuticos Rovi (BME:ROVI) Earnings Strength Keeps Undervalued View In Play

Why the latest earnings and guidance update matters for Laboratorios Farmaceuticos Rovi stock Laboratorios Farmaceuticos Rovi (BME:ROVI) has drawn fresh attention after reporting half year 2026 results with higher sales and net income, while keeping its full year operating revenue growth guidance unchanged. This combination of stronger interim earnings and steady expectations for low to mid single digit operating revenue growth in 2026 provides investors with new information on how the...
BME:VID
BME:VIDPackaging

Vidrala (BME:VID) Reaffirmed Targets, Is The Stock Still Cheap?

Why Vidrala’s latest earnings matter for shareholders Vidrala (BME:VID) has moved back into focus after its half year 2026 earnings on 23 July, with rising profit, firmer margins and a clear reaffirmation of full year financial targets. For the six months to 30 June 2026, Vidrala reported sales of €755.04 million compared with €751.14 million a year earlier. Net income was €117.4 million against €107.84 million, with basic earnings per share at €3.36 versus €3.0667. See our latest analysis...
BME:ENO
BME:ENOConstruction

Elecnor (BME:ENO) Stock Faces Profit Rebound Test After H1 2026 Earnings Return To Black

Elecnor (BME:ENO) has just posted its H1 2026 results with the trailing twelve months showing revenue of €4.4b and basic EPS of €1.52, backed by net income of €128.6m. Over recent reporting periods, the company has seen revenue move from €2.0b and EPS of €0.59 in H1 2025 to €2.4b and EPS of €0.72 in H2 2025, while the prior H2 2024 period was marked by a net income loss of €143.1m on €2.1b of revenue. Overall, margins look steadier than a year ago, leaving investors to consider where...
BME:ART
BME:ARTElectrical

European Stock Picks Possibly Trading Below Intrinsic Value Estimates In July 2026

The European stock market has shown resilience, with the pan-European STOXX Europe 600 Index rising by 0.46% amid robust corporate earnings and geopolitical tensions impacting oil prices. As investors navigate these complex conditions, identifying stocks that may be trading below their intrinsic value can present opportunities for those seeking potential growth in a volatile environment.
BME:ENG
BME:ENGGas Utilities

Enagás (BME:ENG) H1 Earnings Put Its Undervalued Narrative Back In Focus

How Enagás earnings set the context for the stock Enagás (BME:ENG) has just reported half year 2026 results, with sales of €444.63 million and net income of €126.91 million, both lower than the same period a year earlier. Basic and diluted earnings per share from continuing operations were €0.49, compared with €0.68 a year ago. This gives investors fresh information to reassess how the stock’s current price reflects these figures. See our latest analysis for Enagás. Since the H1 2026 earnings...
BME:SAB
BME:SABBanks

Banco de Sabadell (BME:SAB) Stock Faces Margin Pressure As Q2 Net Interest Margin Slips To 1.79%

Banco de Sabadell (BME:SAB) has reported Q2 2026 results with total revenue of €1,396 million and net income of €624 million, setting the tone for how the rest of the year may shape up for shareholders. The company has seen quarterly revenue move from €1,362 million in Q4 2025 to €1,046 million in Q1 2026 and then to €1,396 million in Q2 2026, while basic EPS tracked at €0.0776 in Q4 2025 and €0.0705 in Q1 2026. This gives investors a clearer view of how the top and bottom lines are pacing...
BME:GRF
BME:GRFBiotechs

Does Grifols (BME:GRF) Phase 3 Bet Signal a Deeper Pivot in Its Immunology Strategy?

Grifols recently reported that the first patients have been dosed in two Phase 3 trials to expand U.S. labels for its flagship immunoglobulin therapies, GAMUNEX-C and XEMBIFY, targeting secondary immunodeficiency in certain blood cancers and chronic inflammatory demyelinating polyradiculoneuropathy. This push to broaden indications for existing plasma-derived products highlights how Grifols is trying to deepen its presence in complex, chronic immune-related conditions where immunoglobulin...
BME:A3M
BME:A3MMedia

Atresmedia Corporación De Medios De Comunicación (BME:A3M) Reports Mixed Half Year Earnings, Is It Fully Valued?

Atresmedia Corporación de Medios de Comunicación (BME:A3M) has drawn attention after reporting half year 2026 earnings, with sales of €458.38 million alongside lower net income and earnings per share compared with the previous year. See our latest analysis for Atresmedia Corporación de Medios de Comunicación. Atresmedia Corporación de Medios de Comunicación’s latest half year earnings have landed alongside a share price of €5.08, with a 1 day share price return of 2.83% and a 7 day share...
BME:ART
BME:ARTElectrical

European Export Stocks Getting A Tariff Edge In The US

The new US tariff regime under Section 301 is quietly reshaping the playing field for global exporters, and European stocks are right in the middle of it. With lower duties for key countries like France, the UK, Germany, Spain, Belgium, and Italy, and higher rates for rivals such as Brazil, some European exporters now sit in a more favorable position in US trade. This article looks at how that shift connects to large European companies on our European Exporters screener and reveals 3 stocks...
BME:CIE
BME:CIEAuto Components

Is CIE Automotive (BME:CIE) Undervalued After Strong Half Year Earnings?

CIE Automotive (BME:CIE) has drawn attention after reporting half year 2026 earnings, with sales, revenue, net income and earnings per share all higher than the figures reported a year earlier. See our latest analysis for CIE Automotive. Despite the stronger half year figures, CIE Automotive’s recent share price performance has been weak, with the stock at €25.8 and a year to date share price decline of 14.99%. However, the 5 year total shareholder return of 17.34% points to a more resilient...
BME:REP
BME:REPOil and Gas

Repsol (BME:REP) Stock Looks Cheap On Cash Flow Yet Pricey On Earnings

Repsol’s share price has delivered very strong gains over the past five years, yet there is a clear split in what current valuation tools are signalling, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to sizeable upside while market based multiples suggest the stock is closer to expensive territory. The stock has returned 256.9% over five years, which raises the bar for any further upside to be supported by fundamentals. Recent profit strength and expansion in areas...
BME:IDR
BME:IDRIT

Indra Sistemas (BME:IDR) Stock Tested As Q2 Margin Softness Challenges Bullish Thesis

Indra Sistemas (BME:IDR) has put solid headline figures on the table for Q2 2026, with revenue of about €1.9b, basic EPS of €0.81 and net income of €143.1m, giving investors plenty to weigh as earnings season rolls on. The company has seen revenue move from €1.29b in Q2 2025 to €1.9b in Q2 2026, while quarterly basic EPS has shifted from €0.88 to €0.81 over the same period, framing a mixed picture on the top and bottom lines. With trailing net profit margin sitting below last year’s level,...
BME:ROVI
BME:ROVIPharmaceuticals

Laboratorios Rovi (BME:ROVI) Stock Questioned As One Off Gain Lifts Reported Margins

Laboratorios Farmaceuticos Rovi (BME:ROVI) has released its Q2 2026 results with revenue of €191.7 million and net income of €75.0 million, set against trailing 12 month revenue of €773.1 million, net income of €185.2 million, and Basic EPS of €3.61 that reflects a 40% year over year earnings increase. Over recent quarters the company has seen revenue move from €159.7 million in Q2 2025 to €210.5 million in Q3 2025, €218.4 million in Q4 2025, €152.5 million in Q1 2026 and now €191.7 million...
BME:SAN
BME:SANBanks

Banco Santander (BME:SAN) Stock Highlights 26.6% Net Margin In Q2 2026 Earnings Narrative

Banco Santander (BME:SAN) has posted its Q2 2026 numbers with revenue of about €12.1 billion and net income from continuing operations of €3.7 billion, setting the tone for a results season where profitability stays front and center. The bank has seen quarterly revenue move from €11.6 billion in Q1 2025 to €12.5 billion in Q4 2025 and €12.1 billion in Q1 2026, while basic EPS shifted from €0.19 in Q1 2025 to €0.20 in Q4 2025 and €0.23 in Q1 2026, giving investors a clear run-up of the top and...
BME:REP
BME:REPOil and Gas

Is Repsol (BME:REP) Fully Valued After Its Nexa 95 Renewable Fuel Pilot?

Repsol (BME:REP) is back in focus after BMW Group and Toyota Motor Europe began a six month pilot in Spain using its Nexa 95 renewable gasoline, testing how fully renewable fuel fits into real world transport. See our latest analysis for Repsol. The Nexa 95 pilot comes at a time when Repsol’s share price has been strong, with a 30 day share price return of 17.8% and year to date share price return of 55.27%, alongside a 1 year total shareholder return of 101.92% that points to solid momentum...